Published on 6 Oct 2023 on Zacks via Yahoo Finance
Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study
Merck MRK announced results from the ongoing late-stage AMBASSADOR/KEYNOTE-123 study on Keytruda as an adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (“MIUC”) and locally advanced urothelial carcinoma (“UC”).
Data from the study demonstrated that treatment with Keytruda resulted in a statistically significant and clinically meaningful improvement in the primary endpoint of disease-free survival (“DFS”) compared to observation. The safety profile of the drug was consistent with previously-reported studies.
Management will continue to evaluate the study for its other dual primary endpoint of overall survival (“OS”).